June 25, 2025

Molecular Assay Identifies Patients With Early NSCLC Likely to Benefit From Adjuvant Chemotherapy

Results from an international clinical trial show that a 14-gene molecular assay can help identify patients with early-stage nonsquamous NSCLC who could benefit from adjuvant chemotherapy after surger...

The ASCO Post

June 25, 2025

I Was Expecting to Hear I Have Heart Disease, Not Cancer

In 2022, I had a computed tomography (CT) coronary calcium scan to see whether there were any signs of narrowing or blockage in my heart arteries. Heart disease runs in my family. My father died of a ...

The ASCO Post

June 18, 2025

NCCN Clinical Practice Guidelines in Oncology: 2025 Updates

The National Comprehensive Cancer Network (NCCN) released its first set of Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in 1996, covering eight tumor types. Today, guidelines are availa...

The ASCO Post

June 17, 2025

Early-Phase Trial Shows Activity and Safety of Zongertinib in Previously Treated HER2-Mutant NSCLC

Zongertinib, an investigational oral, HER2-selective, EGFR-sparing tyrosine kinase inhibitor, elicited durable responses and demonstrated clinical benefit in patients with advanced, previously treated...

The ASCO Post

June 17, 2025

Maintenance Therapy With Lurbinectedin Plus Atezolizumab Improves Survival Outcomes in Extensive-Stage Small Cell Lung Cancer

Maintenance treatment with the alkylating agent lurbinectedin plus the monoclonal antibody atezolizumab significantly improved both progression-free survival and overall survival compared with atezoli...

The ASCO Post

June 16, 2025

Several Trials Show Clinical Activity With Osimertinib in Advanced EGFR-Mutant Non–Small Cell Lung Cancer

Updates from several clinical trials of the EGFR tyrosine kinase inhibitor osimertinib across stages and settings of EGFR-mutated non–small cell lung cancer (NSCLC) were presented at the European Lun...

The ASCO Post

June 16, 2025

Final Overall Survival Data: Amivantamab-vmjw Plus Lazertinib vs Osimertinib in EGFR-Mutated Non–Small Cell Lung Cancer

The phase III MARIPOSA trial was a head-to-head comparison of the EGFR tyrosine kinase inhibitor osimertinib and the combination of the bispecific EGF receptor–directed and MET receptor–directed mono...

The ASCO Post

June 16, 2025

Patterns in Adherence to USPSTF Lung Cancer Screening Guidelines

In a study reported as a research letter in JAMA Oncology, Rolle et al found increased overall adherence to the 2021 updated U.S. Preventive Services Task Force (USPSTF) lung cancer screening guidelin...

The ASCO Post

June 16, 2025

FDA Approves Therapy for NSCLC With High c-Met Protein Overexpression

The FDA granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis), a c-Met–directed antibody and microtubule inhibitor conjugate, for adults with locally advanced or metastatic, nonsquamous...

The ASCO Post